Durham, North Carolina, United States
Constella Group, a leading global provider of professional health services, announced that it has entered into a partnership with TCG Lifesciences, an Indian-based contract drug discovery and drug development company. As part of the non-exclusive relationship, Constella and TCG Lifesciences will jointly promote their contract services and identify and promote business opportunities across the two organizations.
Working with TCG Lifesciences' clinical research and development arm (ClinInvent), Constella will expand its clinical trials services into India. Constella will promote ClinInvent's clinical services to its clients interested in conducting clinical trials studies in India. In return, TCG Lifesciences will utilize its contacts within the expanding Indian biotechnology and pharmaceutical markets to promote Constella's services in Europe and the United States. Constella and TCG Lifesciences will work together to explore market opportunities in India for training, quality assurance and regulatory affairs services.
"We are pleased to enter into this partnership with TCG Lifesciences," said Donald A. Holzworth, Constella Group chairman and CEO. "India is attractive to pharmaceutical and biotechnology companies because of the rapid patient recruitment into clinical studies and the country's highly skilled workforce. This partnership allows us to expand our services into new areas of the world."
Commenting on the partnership Mr. Swapan Bhattacharya, managing director, TCG Lifesciences said, "We are confident that the alliance with Constella Group will allow us to further leverage our versatile management team, significant experience in conducting clinical research and data management in India and extensive clinician network across the country. This alliance embodies the strategic fit between the visions of both companies to jointly address current inefficiencies in the drug development process through application of a translational research approach."
The partnership with TCG Lifesciences expands Constella's reach into India. The company has a corporate office in New Delhi with more than 40 employees.
About Constella Group
Constella Group is a leading provider of professional health services worldwide, dedicated to enhancing human health around the world, every day. Through its work in health sciences, international development, and pharmaceutical product development, Constella creates and provides health intelligence to help industry and government clients identify and solve critical problems affecting human health. The company's 1,500 employees serve clients from company headquarters in Durham, N.C., from U.S. offices in Washington, D.C; Rockville and Frederick, Md.; Research Triangle Park, N.C.; Glastonbury, Conn.; Atlanta; and Morgantown, W.Va., from U.K.-based offices in Bath, Oxford and Cambridge; from offices in Cologne, Germany; Paris, France; and New Delhi, India; and from client sites and other offices across the world. For more information, visit www.constellagroup.com.
About TCG Lifesciences
TCG Lifesciences is a leading life sciences research and informatics services organization that enables translational medicine approaches to discovery and development of superior drugs and biologics. TCG Lifesciences offers a new paradigm where focused research and development is seamlessly transitioned from bench to bedside, with laboratory data easily accessed and managed for critical decision making from one enterprise solution across the product development lifecycle.
-- Chembiotek is one of the leaders in biology, chemistry, and pre-clinical research services
-- ClinInvent is uniquely positioned for genomics, proteomics and biomarker research in India, and is already one of the leaders in bio-banking and clinical development services
-- LabVantage is the leading provider of thin-client enterprise laboratory informatics solutions
TCG Lifesciences is headquartered in Kolkata, India, and has operations in Delhi, Mumbai, and Pune as well as in the United States and the United Kingdom.
Source: Business Wire (Business Wire India)